Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

SBFM Sunshine Biopharma Inc

0.0089 (3.41%)
Last Updated: 12:52:53
Delayed by 15 minutes


Draw Mode:

Volume 8,412
Bid Price 0.2601
Ask Price 0.2699
News -
Day High 0.274999


52 Week Range


Day Low 0.251
Company Name Stock Ticker Symbol Market Type
Sunshine Biopharma Inc SBFM NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.0089 3.41% 0.2699 12:52:53
Open Price Low Price High Price Close Price Prev Close
0.251 0.251 0.274999 0.261
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
62 8,412 $ 0.2614894 $ 2,200 - 0.2053 - 1.40
Last Trade Time Type Quantity Stock Price Currency
12:56:50 400 $ 0.2699 USD

Sunshine Biopharma Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
6.95M 25.75M - 4.35M -26.74M -1.04 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Sunshine Biopharma News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No SBFM Message Board. Create One! See More Posts on SBFM Message Board See More Message Board Posts

Historical SBFM Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.280.29510.23140.2756079119,073-0.0101-3.61%
1 Month0.27410.31860.20530.260518290,863-0.0042-1.53%
3 Months0.370.40190.20530.2808975146,266-0.1001-27.05%
6 Months0.6370.660.20530.424382181,071-0.3671-57.63%
1 Year0.7181.400.20530.7870428476,223-0.4481-62.41%
3 Years2.759.870.20534.392,102,115-2.48-90.19%
5 Years2.759.870.20534.392,102,115-2.48-90.19%

Sunshine Biopharma Description

Sunshine Biopharma Inc is a pharmaceutical company focused on the research, development, and commercialization of oncology and antiviral drugs. In addition, it is engaged in the development and commercialization of science-based nutritional supplements. The company is focusing on the development of the licensed Adva-27a anticancer drug, a small molecule that has been shown to be exceptionally effective at destroying Multidrug-Resistant Cancer Cells, including Pancreatic Cancer cells (Panc-1), Small-Cell Lung Cancer cells (H69AR), Breast Cancer cells (MCF-7/MDR) and Uterine Sarcoma cells (MES-SA/Dx5).

Your Recent History

Delayed Upgrade Clock